FDA Approved Label Update for PAH Drug Sotatercept

The FDA has expanded the label for sotatercept following positive clinical trial data in patients with early PAH.

Updated on Sept. 28, 2026 in Heart Disease

Isometric editorial illustration of a medical glass vial resting on a sterile steel plinth, representing medical regulatory updates. — The FDA has updated the label for the drug sotatercept, incorporating phase 3 trial data to support its use for patients in the early stages of pulmonary arterial hypertension. AI Illustration. Upload story photo >

Live Poll

Do you trust that new medical treatments are sufficiently tested before reaching the public?

The FDA has approved a label update for sotatercept-csrk to include phase 3 HYPERION trial data, extending the evidence for its use in patients diagnosed with pulmonary arterial hypertension (PAH) within one year. The drug, administered every three weeks, has shown significant potential in reducing clinical worsening events.

Why it matters

The trial was terminated early due to positive interim results, confirming the efficacy of adding sotatercept to existing treatment regimens. This approval strengthens the clinical pathway for patients in the early stages of their diagnosis.

In the 320-patient HYPERION trial, a 0.7 mg/kg dose of sotatercept reduced the risk of clinical worsening events by 76% compared to a placebo. Adverse events included epistaxis and telangiectasia, with a 3% discontinuation rate due to side effects.

The players

Food and Drug Administration

The federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.

European Respiratory Society

This international organization promotes lung health and develops standardized clinical guidelines for respiratory medicine.

The details

Patients were randomized in a 1:1 ratio to receive either the treatment or a placebo in addition to their background therapy. The European Respiratory Society has since issued a strong recommendation for the inclusion of sotatercept in standard PAH treatment protocols.

September 2026: The European Respiratory Society published updated clinical guidelines.
September 28, 2026: The FDA approved the label update for the drug.

Healthcare
Sept. 21
FDA Regulatory Decisions Expected for Three Drug Firms
Heart Disease
Sept. 23
Acoramidis Reduced ATTR-CM Worsening Risk
Asthma
Sept. 21
Respiratory Research Published Phase 1 Trial Results

Health Landscape

This development reflects a shift toward earlier therapeutic intervention for pulmonary arterial hypertension patients, moving beyond legacy management strategies. The integration of sotatercept marks a milestone in standardizing novel treatments for early-stage disease.

Patients diagnosed with PAH within the last year now have expanded access to a therapy proven to reduce clinical worsening. Individuals should consult their medical providers regarding potential side effects, such as epistaxis and telangiectasia, before adjusting treatment plans.

The takeaway

Early intervention with targeted therapies continues to transform outcomes for those living with chronic pulmonary conditions. Patients should maintain regular communication with their specialists to stay informed about how new label updates might influence their current care protocols.